Stockscreener 앱 받기
1.69
4.32%
0.07
Ocugen Inc 주식(OCGN)의 최신 뉴스
Short Squeeze: Will Ocugen Inc benefit from sector rotation2025 Technical Patterns & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Forecast Cut: Will Ocugen Inc benefit from sector rotationPortfolio Performance Summary & Free Safe Entry Trade Signal Reports - baoquankhu1.vn
Ocugen Shares Stabilize Following Critical Clinical Data Release - AD HOC NEWS
Ocugen Shares Face Scrutiny Over Clinical Data Anomaly - AD HOC NEWS
Ocugen: Why I Don't Read Too Much Into The Selloff On Phase 2 GA Data (NASDAQ:OCGN) - Seeking Alpha
Ocugen reports positive data for gene therapy in geographic atrophy By Investing.com - Investing.com Nigeria
Ocugen Shares Retreat as Clinical Data Fails to Meet Elevated Expectations - AD HOC NEWS
Ocugen’s ArMaDa Trial Sails With Positive Data For OCU410 - Citeline News & Insights
Ocugen (OCGN) Reports 46% Lesion Reduction in OCU410 Mid-Stage Trial - Intellectia AI
Ocugen's Early Gene Therapy Data Shows 46% Drop In Vision Damage - Benzinga
OS Therapies Bone Cancer Trial Data Strengthens FDA Case - Benzinga
Ocugen Faces Mounting Challenges in Vaccine Market - StocksToTrade
Ocugen Faces Sharp Stock Drop Amid Business Challenges - timothysykes.com
Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - Ocugen, Inc.
Ocugen Reports Encouraging 12-Month Data for OCU410 - TipRanks
Ocugen (OCGN) Reports Promising Mid-Stage Trial Results for OCU410 - GuruFocus
Ocugen posts mid-stage trial data for GA therapy (OCGN:NASDAQ) - Seeking Alpha
Ocugen reports positive data for gene therapy in geographic atrophy - Investing.com
Ocugen rises as gene therapy shows promise for blinding eye disease - TradingView — Track All Markets
Ocugen announces positive preliminary phase 2 data from Ocu410 modifier gene therapy for geographic atrophy secondary to dry age-related macular degeneration - marketscreener.com
Eye gene therapy for geographic atrophy slows lesions 46% in study - Stock Titan
Ocugen Inc. Stock Rises Wednesday, Outperforms Market - 富途牛牛
Ocugen Shares Surge Ahead of Key Clinical Data Announcement - AD HOC NEWS
Ocugen (NASDAQ:OCGN) Hits New 1-Year HighHere's Why - MarketBeat
Ocugen Shares Surge Ahead of Pivotal Clinical Data Release - AD HOC NEWS
Ocugen to host webcast on OCU410 Phase 2 clinical trial results - Investing.com Nigeria
Ocugen (NASDAQ:OCGN) Trading Down 5.9%Should You Sell? - MarketBeat
Why The Narrative Around Ocugen (OCGN) Is Shifting After New Fair Value Updates - Yahoo Finance
Ocugen publishes phase 1 GARDian1 gene therapy data for Stargardt disease - Ophthalmology Times
Ocugen Shares Surge on Clinical Validation and Upcoming Catalyst - AD HOC NEWS
Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data - Ocugen, Inc.
Ocugen to Host Conference Call Discussing One-Year Data from OCU410 Phase 2 ArMaDa Clinical Trial - Quiver Quantitative
Ocugen Shares Surge on Promising Gene Therapy Trial Results - AD HOC NEWS
Ocugen reports positive Phase 1 trial results for Stargardt disease therapy - Investing.com Nigeria
Ocugen Shares Surge on Promising Gene Therapy Trial Data - AD HOC NEWS
OCGN stock rises pre-market after gene therapy data shows promise in rare eye disorder - MSN
Ocugen (NASDAQ:OCGN) Shares Up 9%Time to Buy? - MarketBeat
Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy - Ocugen, Inc.
Ocugen announces publication of Phase 1 GARDian1 trial results for OCU410ST - TipRanks
OCGN Stock Rises Pre-Market After Gene Therapy Data Shows Promise In Rare Eye Disorder - Stocktwits
Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference - marketscreener.com
Ocugen (OCGN) Reveals Positive Trial Results for Gene Therapy OC - GuruFocus
Ocugen, Inc. Reports Positive Phase 1 Trial Results for OCU410ST in Stargardt Disease, Highlighting Safety and Efficacy - Quiver Quantitative
Gene therapy trial slows eye damage in Stargardt patients with no options - Stock Titan
Ocugen Faces Pivotal Investor Test at Key Healthcare Conference - AD HOC NEWS
Is Social Media Hype Reshaping Ocugen’s (OCGN) Gene Therapy Story More Than Its Pipeline Progress? - Sahm
Ocugen (OCGN) Valuation Check As Social Media Speculation Lifts Interest In Gene Therapy Prospects - Yahoo Finance
Ocugen Eyes a Breakout Year as It Takes Center Stage at JPM Healthcare - MyChesCo
Ocugen Announces Q2 2025 Financial Results Call and Business Update - MSN
Is Social Media Now Defining Ocugen's (OCGN) Gene Therapy Investment Story More Than Its Science? - Yahoo Finance
How Ocugen Inc. stock performs in stagflation2025 Year in Review & Stepwise Entry and Exit Trade Signals - ulpravda.ru
Trend Report: Can Ocugen Inc. (2H51) stock sustain revenue momentumStock Surge & Detailed Earnings Play Alerts - ulpravda.ru
Can Ocugen Inc. (2H51) stock sustain revenue momentumRecession Risk & AI Driven Stock Price Forecasts - ulpravda.ru
Ocugen (OCGN) Valuation Check As Social Media Buzz Highlights Its High Risk High Reward Pipeline - simplywall.st
Ocugen Inc Is Exploding Again: Hidden Gem or Total Meme Stock? - AD HOC NEWS
Can Ocugen Inc. stock withstand economic slowdownSector Performance Review & Low Risk Wealth Plans - ulpravda.ru
4.73%
0.92%
자본화:
|
볼륨(24시간):